VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

BoHV-4-A-IgK-VP2gD
Vaccine Information
  • Vaccine Ontology ID: VO_0004686
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Cattle
  • Preparation: BoHV-4-based vector cloned as a bacterial artificial chromosome (BAC) was engineered to express the bluetongue virus (BTV) immune-dominant glycoprotein VP2 provided of a heterologous signal peptide to its amino terminal and a trans-membrane domain to its carboxyl terminal (IgK-VP2gDtm), to allow VP2 expression targeting to the cell membrane fraction (Franceschi et al., 2011).
  • Immunization Route: Other
Host Response

Mouse Response

  • Host Strain: α/β interferon receptor knockout (IFNAR(-/-)) mice
  • Vaccination Protocol: IFNAR(-/-) mice intraperitoneally inoculated twice with BoHV-4-A-IgK-VP2gDtm at different time points.
  • Vaccine Immune Response Type: VO_0000287
  • Immune Response: Mice eveloped serum neutralizing antibodies against BTV .
  • Side Effects: A pre-challenge experiment was performed to test BoHV-4 safety on adult α/β interferon receptor knockout (IFNAR(-/-)) mice, a newly generated bluetongue laboratory animal model. BoHV-4 infected IFNAR(-/-) mice did not show clinical signs even following the inoculation of BoHV-4 intra-cerebrally, although many areas of the brain got transduced (Franceschi et al., 2011).
  • Challenge Protocol: a lethal dose of BTV-8 as used for challenge (Franceschi et al., 2011).
  • Efficacy: Vaccinated mice showed a strongly reduced viremia and a longer survival time after challenge (Franceschi et al., 2011).
References
Franceschi et al., 2011: Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, Ortego J, Donofrio G. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine. 2011; 29(16); 3074-3082. [PubMed: 21320537].